{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.8","upperLimit":"100","value":"82.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The addition of vorinostat to tacrolimus and methotrexate for GVHD prophylaxis will be considered feasible if 60% or more of the planned doses are administered.","dispersionType":"Full Range","groups":[{"description":"Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.","id":"OG000","title":"Supportive Care (Vorinostat, Tacrolimus, Methotrexate)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to day 30","title":"Mean Percent of Planned Dose Administered","type":"SECONDARY","unitOfMeasure":"percent of dose administered"}